Key Points
- Director Philip Laskawy sold 2,844 shares on March 5 at an average price of $80.36 for about $228,544, reducing his ownership by 11.47% to 21,961 shares (≈$1.76M); the sale was disclosed in an SEC filing.
- Henry Schein beat quarterly expectations, reporting $1.34 EPS vs. $1.30 expected and $3.44B in revenue (vs. $3.34B), and set FY2026 guidance of $5.230–5.370 EPS.
- Shares opened at $77.60 (down ~3.2%) and analyst sentiment is mixed—an average rating of "Hold" with an average price target of $85.58 (six Buy, six Hold, one Sell).
Henry Schein, Inc. (NASDAQ:HSIC - Get Free Report) Director Philip Laskawy sold 2,844 shares of the stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $80.36, for a total value of $228,543.84. Following the sale, the director owned 21,961 shares in the company, valued at approximately $1,764,785.96. This represents a 11.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Henry Schein Trading Down 3.2%
Shares of NASDAQ:HSIC opened at $77.60 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.38 and a quick ratio of 0.76. Henry Schein, Inc. has a 1 year low of $60.56 and a 1 year high of $89.29. The company has a market cap of $8.90 billion, a P/E ratio of 23.73, a PEG ratio of 2.37 and a beta of 0.88. The stock's fifty day moving average price is $78.20 and its 200-day moving average price is $72.57.
Henry Schein (NASDAQ:HSIC - Get Free Report) last posted its quarterly earnings data on Tuesday, February 24th. The company reported $1.34 earnings per share for the quarter, beating analysts' consensus estimates of $1.30 by $0.04. The business had revenue of $3.44 billion for the quarter, compared to analysts' expectations of $3.34 billion. Henry Schein had a net margin of 3.02% and a return on equity of 15.16%. The business's revenue was up 7.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.19 earnings per share. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Sell-side analysts expect that Henry Schein, Inc. will post 4.74 earnings per share for the current year.
Hedge Funds Weigh In On Henry Schein
Several large investors have recently bought and sold shares of HSIC. Hsbc Holdings PLC raised its stake in Henry Schein by 2.5% during the 4th quarter. Hsbc Holdings PLC now owns 123,550 shares of the company's stock valued at $9,353,000 after acquiring an additional 3,014 shares during the last quarter. Reflection Asset Management bought a new position in Henry Schein during the 4th quarter worth approximately $516,000. Compound Planning Inc. acquired a new position in shares of Henry Schein in the 4th quarter worth approximately $275,000. Corient Private Wealth LLC lifted its stake in Henry Schein by 5.4% during the fourth quarter. Corient Private Wealth LLC now owns 37,019 shares of the company's stock worth $2,798,000 after purchasing an additional 1,906 shares during the last quarter. Finally, Mercer Global Advisors Inc. ADV increased its stake in Henry Schein by 7.8% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 4,318 shares of the company's stock valued at $326,000 after purchasing an additional 312 shares during the last quarter. Hedge funds and other institutional investors own 96.62% of the company's stock.
Analysts Set New Price Targets
A number of equities research analysts have weighed in on HSIC shares. Robert W. Baird set a $100.00 target price on Henry Schein and gave the company an "outperform" rating in a research report on Monday, February 23rd. Wall Street Zen upgraded Henry Schein from a "buy" rating to a "strong-buy" rating in a research report on Saturday, February 28th. Barrington Research set a $97.00 target price on Henry Schein and gave the stock an "outperform" rating in a research note on Wednesday, February 25th. UBS Group upped their price target on Henry Schein from $79.00 to $87.00 and gave the company a "neutral" rating in a research note on Wednesday, February 25th. Finally, Mizuho increased their price target on Henry Schein from $81.00 to $88.00 and gave the stock a "neutral" rating in a report on Wednesday, February 25th. Six equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Henry Schein has an average rating of "Hold" and an average price target of $85.58.
View Our Latest Research Report on HSIC
Henry Schein Company Profile
(
Get Free Report)
Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.
In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
